Your Top 50 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Thomas C. C. Yau, J.W. Park, Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline and 14 more
- Rank
- 14 of 4,622
- Percentile
- top 0.4%
- Where
- Annals of Oncology, 2019
- Citations
- 647
From the 2019 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.